{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:36:09Z","timestamp":1787808969610,"version":"build-2784847793"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,9]]},"abstract":"<jats:p>Polycystic ovary syndrome (PCOS) is a disease caused by excessive ovarian androgen secretion due to hypothalamic\u2013pituitary\u2013ovarian hormone abnormalities. We retrospectively investigated the treatment status of patients diagnosed with PCOS who visited a domestic tertiary hospital in order to analyze the use patterns and safety of drugs. Patients diagnosed with PCOS between July 2014 and September 2022 were examined, excluding patients younger than 13 years and those not receiving medication. Patients aged 21 years or younger were designated as the adolescent group and patients aged 22 years or older were designated as the adult group for comparative statistical analysis. The total number of patients was 212, including 105 adolescents (49.5%) and 107 adults (50.5%). Comorbidities were ovarian cyst in 20 (9.4%) patients, endometriosis in 19 (9%), diabetes in 14 (6.6%), thyroid dysfunction in 12 (5.7%), hypertension in 10 (4.7%), dyslipidemia in 10 (4.7%), and androgenic alopecia in 6 (2.8%). Symptoms were oligomenorrhea in 91 (42.9%) patients, amenorrhea in 72 (34%), hirsutism in 36 (17%), acne in 24 (11.3%), and infertility in 10 (4.7%). During the study period, 114 patients (53.8%) were prescribed medroxyprogesterone acetate (MPA), 66 (31.1%) were given oral contraceptives (specifically, ethinyl estradiol +\u2005drospirenone prescribed to 52 (24.5%)), and 17 (8%) were concurrently prescribed MPA and oral contraceptives. Forty-five (21.2%) patients changed prescriptions, with 10 (22.2%) switching due to side effects and 8 (17.8%) due to a therapeutic failure. A total of 5 patients (2.4%) discontinued the drug. Adverse drug reactions occurred in 15 patients (7.1%), with 5 being adolescents (4.8%) and 10 being adults (9.3%). MPA alone and ethinyl estradiol with drospirenone were the most prescribed medications for PCOS. Over the study, 45 patients changed prescriptions, 50 were lost to follow-up, and 5 adults discontinued medications.<\/jats:p>","DOI":"10.1097\/md.0000000000039055","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T14:41:59Z","timestamp":1723214519000},"page":"e39055","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Assessing medication use patterns among patients with polycystic ovary syndrome at a tertiary care teaching hospital in South Korea: A retrospective study"],"prefix":"10.1097","volume":"103","author":[{"given":"Ji Hye","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Chonbuk National University Hospital, Jeonju-si, Jeollabuk-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Kyung","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chonbuk National University Hospital, Jeonju-si, Jeollabuk-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Cho","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chonbuk National University Hospital, Jeonju-si, Jeollabuk-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5025-9788","authenticated-orcid":false,"given":"Young-Mo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(07)61345-2","article-title":"Polycystic ovary syndrome.","volume":"370","author":"Norman","year":"2007","journal-title":"Lancet"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0002-9378(15)30642-6","article-title":"Amenorrhea associated with bilateral polycystic ovaries.","volume":"29","author":"Stein","year":"1935","journal-title":"Am J Obstet Gynecol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3390\/jcm12041454","article-title":"Polycystic ovary syndrome: etiology, current management, and future therapeutics.","volume":"12","author":"Singh","year":"2023","journal-title":"J Clin Med"},{"key":"R4-20250503","article-title":"Statistics on diseases of national interest."},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3803\/EnM.2011.26.3.203","article-title":"Polycystic ovary syndrome in Korean women: clinical characteristics and diagnostic criteria.","volume":"26","author":"Sung","year":"2011","journal-title":"Endocrinol Metab"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bpobgyn.2016.05.003","article-title":"Androgen excess: investigations and management.","volume":"37","author":"Lizneva","year":"2016","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/humupd\/dmg044","article-title":"Ultrasound assessment of the polycystic ovary: international consensus definitions.","volume":"9","author":"Balen","year":"2003","journal-title":"Hum Reprod Update"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S37559","article-title":"Epidemiology, diagnosis, and management of polycystic ovary syndrome.","volume":"6","author":"Sirmans","year":"2013","journal-title":"Clin Epidemiol"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40618-016-0523-8","article-title":"New markers of insulin resistance in polycystic ovary syndrome.","volume":"40","author":"Polak","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.contraception.2010.02.009","article-title":"Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.","volume":"82","author":"Kriplani","year":"2010","journal-title":"Contraception"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s40618-016-0466-0","article-title":"Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI.","volume":"39","author":"Sabbadin","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"R12-20250503","first-page":"415","article-title":"Insulin resistance and fertility in polycystic ovary syndrome.","volume":"1","author":"Fica","year":"2008","journal-title":"J Med Life"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fendo.2020.00516","article-title":"Fundamental concepts and novel aspects of polycystic ovarian syndrome: expert consensus resolutions.","volume":"11","author":"Aversa","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.","volume":"110","author":"Teede","year":"2018","journal-title":"Fertil Steril"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.","volume":"33","author":"Diamanti-Kandarakis","year":"2012","journal-title":"Endocr Rev"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.3346\/jkms.2020.35.e406","article-title":"Trend of menarcheal age among Korean girls.","volume":"35","author":"Seo","year":"2020","journal-title":"J Korean Med Sci"},{"key":"R17-20250503","first-page":"71","article-title":"Clinical characteristics of Korean Daegu\u00b7Kyungpook PCOS women.","volume":"36","author":"Bae","year":"2009","journal-title":"Korean J Reprod Med"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.tjog.2021.11.009","article-title":"Polycystic ovarian syndrome-current pharmacotherapy and clinical implications.","volume":"61","author":"Rashid","year":"2022","journal-title":"Taiwan J Obstet Gynecol"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1210\/jc.2007-2437","article-title":"Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline.","volume":"93","author":"Martin","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.","volume":"81","year":"2004","journal-title":"Fertil Steril"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.3802\/jgo.2016.27.e8","article-title":"Therapeutic options for management of endometrial hyperplasia.","volume":"27","author":"Chandra","year":"2016","journal-title":"J Gynecol Oncol"},{"key":"R22-20250503","first-page":"336","article-title":"Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches.","volume":"38","author":"Ndefo","year":"2013","journal-title":"P T"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijgo.2008.11.039","article-title":"Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome.","volume":"105","author":"Haydardedeoglu","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijgo.2008.05.017","article-title":"Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome.","volume":"103","author":"Ozdemir","year":"2008","journal-title":"Int J Gynaecol Obstet"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1210\/jc.2002-020294","article-title":"The effects of short-term medroxyprogesterone acetate and micronized progesterone on glucose metabolism and lipid profiles in patients with polycystic ovary syndrome: a prospective randomized study.","volume":"87","author":"Bagis","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpag.2013.09.011","article-title":"A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome.","volume":"27","author":"Chung","year":"2014","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2006.08.8344","article-title":"Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.","volume":"25","author":"Ushijima","year":"2007","journal-title":"J Clin Oncol"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ygyno.2003.07.002","article-title":"Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone.","volume":"91","author":"Vereide","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R29-20250503","first-page":"75","article-title":"Metformin and polycystic ovary syndrome.","volume":"1","author":"Omran","year":"2007","journal-title":"Int J Health Sci (Qassim)"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"27","DOI":"10.24304\/kjcp.2022.32.1.27","article-title":"Transitional care for high-risk elderly patients pre\/post discharge by collaboration between general hospital and community pharmacy: a pilot study.","volume":"32","author":"Park","year":"2022","journal-title":"Korean J Clin Pharm"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"102162","DOI":"10.1016\/j.eclinm.2023.102162","article-title":"Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials.","volume":"63","author":"Alesi","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R32-20250503","first-page":"25","article-title":"Nonpharmacologic management of symptoms in females with polycystic ovary syndrome: a narrative review.","volume":"119","author":"Speelman","year":"2019","journal-title":"J Am Osteopath Assoc"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/humupd\/dmy045","article-title":"Overview of systematic reviews of non-pharmacological interventions in women with polycystic ovary syndrome.","volume":"25","author":"Pundir","year":"2019","journal-title":"Hum Reprod Update"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:39:39Z","timestamp":1746304779000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":33,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039055","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]}}}